Keros Therapeutics (NASDAQ:KROS) Shares Down 3.7% – What’s Next?

Keros Therapeutics, Inc. (NASDAQ:KROS)’s stock price fell 3.7% on Thursday . The stock traded as low as $20.13 and last traded at $20.0680. 63,757 shares changed hands during mid-day trading, a decline of 93% from the average session volume of 934,736 shares. The stock had previously closed at $20.83.

Analysts Set New Price Targets

Several research firms have issued reports on KROS. Wedbush upped their price objective on Keros Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a research note on Thursday, November 6th. Bank of America boosted their price target on Keros Therapeutics from $18.00 to $19.00 and gave the company a “neutral” rating in a research note on Friday, November 28th. Zacks Research upgraded shares of Keros Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, November 7th. Oppenheimer restated an “outperform” rating and set a $27.00 price objective (up from $23.00) on shares of Keros Therapeutics in a research report on Wednesday, November 12th. Finally, Wells Fargo & Company lowered their price objective on Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating for the company in a research note on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $21.38.

Keros Therapeutics Price Performance

The company’s fifty day simple moving average is $17.19 and its 200 day simple moving average is $15.53. The firm has a market capitalization of $612.14 million, a PE ratio of 13.02, a P/E/G ratio of 0.26 and a beta of 0.89.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, November 5th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.93. The business had revenue of $14.26 million for the quarter, compared to analyst estimates of $4.22 million. Keros Therapeutics had a return on equity of 9.51% and a net margin of 26.12%.The company’s quarterly revenue was up 3585.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.41) EPS. On average, analysts anticipate that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Keros Therapeutics news, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total value of $84,975,125.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the company’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total value of $95,659,436.00. The disclosure for this sale is available in the SEC filing. Company insiders own 20.60% of the company’s stock.

Hedge Funds Weigh In On Keros Therapeutics

A number of hedge funds have recently modified their holdings of the company. Tower Research Capital LLC TRC grew its holdings in Keros Therapeutics by 149.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after buying an additional 1,888 shares in the last quarter. Farther Finance Advisors LLC bought a new stake in shares of Keros Therapeutics in the 3rd quarter worth about $47,000. CWM LLC boosted its position in shares of Keros Therapeutics by 87.5% during the second quarter. CWM LLC now owns 5,000 shares of the company’s stock valued at $67,000 after buying an additional 2,333 shares during the period. SG Americas Securities LLC bought a new position in Keros Therapeutics in the 3rd quarter valued at $103,000. Finally, Police & Firemen s Retirement System of New Jersey grew its holdings in shares of Keros Therapeutics by 29.7% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 8,257 shares of the company’s stock worth $110,000 after purchasing an additional 1,892 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.